Interim Monitoring Visit (IMV)

An Interim Monitoring Visit (IMV) is the routine, periodic monitoring contact — on-site or remote — that a sponsor or its Clinical Research Associate (CRA) conducts throughout a clinical trial site’s active conduct period: after the site has been initiated and started enrolling or following participants, and before the site closes out. It is the visit type site staff and CRAs typically mean when they say a ‘monitoring visit’ without qualification, since it is the one that repeats — often every 4-8 weeks depending on the trial’s risk-based monitoring plan — for as long as the site remains active, unlike the site’s single Site Initiation Visit or single Close-Out Visit.

What ICH E6(R2) requires an IMV to check

ICH E6(R2) Section 5.18 (Monitoring) frames the purpose of monitoring generally, and Section 5.18.3 sets out its three goals: confirming that the rights and well-being of human subjects are protected; confirming that reported trial data are accurate, complete, and verifiable from source documents; and confirming that the trial is conducted in compliance with the currently approved protocol/amendments, GCP, and applicable regulatory requirements. Section 5.18.4 lists the specific activities a monitor is expected to carry out to meet those goals, and most of them are the recurring, interim-visit work: verifying informed consent was obtained and documented correctly for each newly enrolled participant; performing Source Data Verification (SDV) — comparing case report form (CRF) entries against source documents such as clinic notes, lab reports, and imaging reads; checking investigational product (IP) accountability — supply, storage conditions, dispensing records, and reconciliation against what has actually been administered; reviewing the site’s essential/regulatory documents (the Investigator Site File) for currency, including IRB/ethics continuing-review approvals and any protocol amendments; and confirming adverse events and serious adverse events have been identified, documented, and reported within the required timelines. ICH E6(R2) 5.18.6 further requires that reports of these monitoring visits — whether on-site or centralized — be submitted to the sponsor (including appropriate sponsor management and CRO staff) in a timely manner, with sufficient detail to allow follow-up on findings.

How IMV frequency and depth get set

Neither ICH E6(R2) nor FDA guidance mandates a fixed interval or a fixed depth of review (such as 100% SDV) for interim visits. Since FDA’s 2013 risk-based monitoring guidance and the ICH E6(R2) addendum’s 2016 emphasis on quality management, sponsors are explicitly encouraged to set IMV frequency and scope according to a documented, risk-based monitoring plan: sites with higher enrollment, more complex procedures, safety signals, or prior-visit findings are typically monitored more often and more thoroughly than low-risk, low-enrollment sites. A trial may also blend on-site IMVs with centralized monitoring — remote, statistical review of accumulating data across sites between or instead of some on-site visits — rather than relying on on-site IMVs alone for every check.

Where the IMV sits in the visit sequence

A trial site typically moves through a standard sequence of monitoring visit types, and the IMV is the recurring middle stage, not the first or last: a Site Initiation Visit (SIV) activates the site before enrollment begins (training staff, confirming regulatory documents are in place, and formally authorizing the site to enroll); Interim Monitoring Visits then recur throughout active conduct; and a Close-Out Visit (COV) closes the site after the last participant has completed the trial and outstanding queries are resolved, performing a final reconciliation of IP, source documents, and essential documents. Some trials also include an earlier Site Qualification/Pre-Study Visit before selection, assessing whether a prospective site has the facilities, staff, and patient population to run the trial at all — a feasibility assessment, not a monitoring visit, since it happens before a site has even been selected. Confusing IMVs with any of these adjacent visit types is a common source of ambiguity in monitoring plans and site-visit logs; the defining feature of an IMV is that it is one of a recurring series conducted during active, ongoing site conduct, not a one-time activation or closure event.

Related terms

• Source Data Verification (SDV) — the specific data-checking technique performed during an IMV (and, remotely, during centralized monitoring).
• Centralized Monitoring — remote, statistical monitoring of accumulating data across sites, used alongside or in place of some on-site IMVs under a risk-based monitoring plan.
• Site Initiation Visit (SIV) — the one-time visit that activates a site before IMVs begin.
• Clinical Research Associate (CRA) — the role that most commonly conducts IMVs.